Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Davidson Capital Management Inc.

Davidson Capital Management Inc. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,672 shares of the company’s stock after acquiring an additional 1,279 shares during the quarter. Davidson Capital Management Inc.’s holdings in Medpace were worth $3,213,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. R Squared Ltd purchased a new position in shares of Medpace in the 4th quarter valued at about $30,000. Stone House Investment Management LLC acquired a new stake in Medpace in the third quarter valued at approximately $33,000. Ashton Thomas Securities LLC purchased a new stake in shares of Medpace in the third quarter valued at approximately $37,000. Capital Performance Advisors LLP acquired a new position in shares of Medpace during the 3rd quarter worth approximately $46,000. Finally, True Wealth Design LLC raised its stake in shares of Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after buying an additional 168 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 7.5 %

Shares of NASDAQ MEDP opened at $327.86 on Wednesday. The company has a 50-day moving average of $344.13 and a 200 day moving average of $349.34. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The stock has a market cap of $10.19 billion, a PE ratio of 28.71, a P/E/G ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.